Disease-site-specific liposomal formulation
AssigneesOsaka University, Cuorips Inc.
InventorsYoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi
Life of this patent
Estimating the term…
Abstract
The present invention provides clinically applicable, safe and convenient, pharmaceutical compositions and methods for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment methods comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.
Claims14
A method for treating an ischemic organ disorder comprising administering a pharmaceutical composition into a subject, wherein the pharmaceutical composition comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein, wherein the stealth liposome has an average particle size of 50 to 200 nm, and comprises 5 to 50 parts by weight of a phospholipid and 0.05 to 5 parts by weight of PEG-modified phosphoethanolamine, per part by weight of the prostaglandin I2 receptor agonist.
Dependencies are inferred from the claim text.